Erasca Inc

General ticker "ERAS" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.2B

Erasca Inc follows the US Stock Market performance with the rate: 54.4%.

Estimated limits based on current volatility of 3.1%: low 2.38$, high 2.53$

Factors to consider:

  • Price in estimated range
  • Earnings for 9 months up through Q3 are close to our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.29$, 3.43$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.68$, 4.13$]

Financial Metrics affecting the ERAS estimates:

  • Negative: Non-GAAP EPS, $ of -0.83 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -26.22 <= 2.35
  • Positive: -0.96 < Investing cash flow per share, $ of -0.61
  • Negative: negative Net income
  • Positive: Interest expense per share, $ of 0 <= 0

Similar symbols

Short-term ERAS quotes

Long-term ERAS plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $124.88MM $247.45MM $141.53MM
Operating Income $-124.88MM $-247.45MM $-141.53MM
Non-Operating Income $2.12MM $4.64MM $16.48MM
Interest Expense $0.00MM $201.36MM $0.00MM
R&D Expense $73.92MM $112.46MM $103.82MM
Income(Loss) $-122.76MM $-242.81MM $-125.04MM
Taxes $27.33MM $-4.64MM $0.00MM
Profit(Loss) $-150.09MM $-238.16MM $-125.04MM
Stockholders Equity $456.53MM $411.85MM $316.69MM
Assets $501.42MM $514.91MM $395.30MM
Operating Cash Flow $-79.60MM $-103.26MM $-101.22MM
Capital expenditure $18.89MM $16.55MM $1.77MM
Investing Cash Flow $-64.59MM $-71.08MM $-91.22MM
Financing Cash Flow $439.40MM $98.08MM $1.29MM
Earnings Per Share* $-1.26 $-1.95 $-0.83

* EPS are Split Adjusted, recent splits may be reflected with a delay.